SE8903003D0 - Novel medical use - Google Patents

Novel medical use

Info

Publication number
SE8903003D0
SE8903003D0 SE8903003A SE8903003A SE8903003D0 SE 8903003 D0 SE8903003 D0 SE 8903003D0 SE 8903003 A SE8903003 A SE 8903003A SE 8903003 A SE8903003 A SE 8903003A SE 8903003 D0 SE8903003 D0 SE 8903003D0
Authority
SE
Sweden
Prior art keywords
medical use
novel medical
thioredoxin
interferons
immunoglobulins
Prior art date
Application number
SE8903003A
Other languages
English (en)
Swedish (sv)
Inventor
N A Ros
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE8903003A priority Critical patent/SE8903003D0/xx
Publication of SE8903003D0 publication Critical patent/SE8903003D0/xx
Priority to IL95583A priority patent/IL95583A0/xx
Priority to IE323390A priority patent/IE903233A1/en
Priority to CA002065454A priority patent/CA2065454A1/en
Priority to PCT/SE1990/000578 priority patent/WO1991004320A1/en
Priority to GR900100679A priority patent/GR1001151B/el
Priority to AU64336/90A priority patent/AU641942B2/en
Priority to EP90913906A priority patent/EP0489113A1/en
Priority to JP2512956A priority patent/JPH05500216A/ja
Priority to DD90343919A priority patent/DD298056A5/de
Priority to HU92821A priority patent/HUT62932A/hu
Priority to PT95284A priority patent/PT95284A/pt
Priority to NO920911A priority patent/NO920911D0/no
Priority to BG096034A priority patent/BG96034A/bg
Priority to FI921058A priority patent/FI921058A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01008—Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE8903003A 1989-09-12 1989-09-12 Novel medical use SE8903003D0 (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE8903003A SE8903003D0 (sv) 1989-09-12 1989-09-12 Novel medical use
IL95583A IL95583A0 (en) 1989-09-12 1990-09-04 Pharmaceutical compositions comprising thioredoxin
IE323390A IE903233A1 (en) 1989-09-12 1990-09-06 Novel medical use
HU92821A HUT62932A (en) 1989-09-12 1990-09-10 Process for producing pharmaceutical compositions comprising thioredoxin
AU64336/90A AU641942B2 (en) 1989-09-12 1990-09-10 The use of thioredoxin in the treatment of malignantly transformed cells in animals and man
PCT/SE1990/000578 WO1991004320A1 (en) 1989-09-12 1990-09-10 The use of thioredoxin in the treatment of malignantly transformed cells in animals and man
GR900100679A GR1001151B (el) 1989-09-12 1990-09-10 Νεα xρηση θειορεδοξινης
CA002065454A CA2065454A1 (en) 1989-09-12 1990-09-10 Use of thioredoxin in the treatment of malignantly transformed cells in animals and man
EP90913906A EP0489113A1 (en) 1989-09-12 1990-09-10 The use of thioredoxin in the treatment of malignantly transformed cells in animals and man
JP2512956A JPH05500216A (ja) 1989-09-12 1990-09-10 新規な医療用途
DD90343919A DD298056A5 (de) 1989-09-12 1990-09-10 Arzneimittel
PT95284A PT95284A (pt) 1989-09-12 1990-09-11 Novo metodo de tratamento de doencas malignas com tioredoxina
NO920911A NO920911D0 (no) 1989-09-12 1992-03-06 Anvendelse av tioredoksin for behandling av maligne transformerte celler i dyr og mennesker
BG096034A BG96034A (bg) 1989-09-12 1992-03-11 Приложение на тиоредоксин за лечението на злокачествено трансформирани клетки при животни и хора
FI921058A FI921058A0 (fi) 1989-09-12 1992-03-11 Anvaendning av thioredoxin vid behandling av elakartade transformade celler i djur och maenniska.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8903003A SE8903003D0 (sv) 1989-09-12 1989-09-12 Novel medical use

Publications (1)

Publication Number Publication Date
SE8903003D0 true SE8903003D0 (sv) 1989-09-12

Family

ID=20376862

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8903003A SE8903003D0 (sv) 1989-09-12 1989-09-12 Novel medical use

Country Status (12)

Country Link
EP (1) EP0489113A1 (xx)
JP (1) JPH05500216A (xx)
AU (1) AU641942B2 (xx)
CA (1) CA2065454A1 (xx)
DD (1) DD298056A5 (xx)
FI (1) FI921058A0 (xx)
GR (1) GR1001151B (xx)
HU (1) HUT62932A (xx)
IE (1) IE903233A1 (xx)
PT (1) PT95284A (xx)
SE (1) SE8903003D0 (xx)
WO (1) WO1991004320A1 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
WO1998000160A1 (en) * 1996-06-28 1998-01-08 Nat Jewish Ct Immun & Respirat USE OF THIOREDOXIN-LIKE MOLECULES FOR INDUCTION OF MnSOD TO TREAT OXIDATIVE DAMAGE
WO1998024472A1 (en) * 1996-12-06 1998-06-11 Garth Powis Uses of thioredoxin
US6689775B2 (en) 1999-06-03 2004-02-10 Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona Uses of thioredoxin
US5919657A (en) * 1997-04-09 1999-07-06 Incyte Pharmaceuticals, Inc. Nucleic acids encoding human thioredoxin protein; related reagents
US7585645B2 (en) 1997-05-27 2009-09-08 Sembiosys Genetics Inc. Thioredoxin and thioredoxin reductase containing oil body based products
EP1049772A1 (en) 1998-01-30 2000-11-08 Genesense Technologies, Inc. Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth
EA004107B1 (ru) 1998-08-11 2003-12-25 Айдек Фармацевтикалс Корпорэйшн Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
AU761844C (en) 1998-11-09 2004-09-23 F. Hoffmann-La Roche Ag Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
EP1332212A2 (en) * 2000-08-25 2003-08-06 Curagen Corporation Proteins and nucleic acids encoding same
JP2006513147A (ja) 2002-09-10 2006-04-20 ナショナル ジューイッシュ メディカル アンド リサーチ センター 粘液または痰の液化のための生成物および処理
MX2015013040A (es) 2013-03-15 2016-05-24 Orpro Therapeutics Inc Producto y proceso para normalización de la viscosidad del moco.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2633295B2 (ja) * 1987-06-12 1997-07-23 味の素株式会社 ヒトａｄｆをコードする遺伝子

Also Published As

Publication number Publication date
HU9200821D0 (en) 1992-05-28
AU641942B2 (en) 1993-10-07
IE903233A1 (en) 1991-03-27
GR900100679A (en) 1992-01-20
JPH05500216A (ja) 1993-01-21
AU6433690A (en) 1991-04-18
DD298056A5 (de) 1992-02-06
HUT62932A (en) 1993-06-28
FI921058A0 (fi) 1992-03-11
CA2065454A1 (en) 1991-03-13
EP0489113A1 (en) 1992-06-10
GR1001151B (el) 1993-05-24
WO1991004320A1 (en) 1991-04-04
PT95284A (pt) 1991-08-14

Similar Documents

Publication Publication Date Title
SE8903003D0 (sv) Novel medical use
ES2062355T3 (es) Composicion farmaceutica que comprende loratadina, ibuprofeno y pseudoefedrina.
CA2075060A1 (en) Novel vehicle gases and their use in medical preparations
DK0751959T3 (da) Modificerede polypeptider med forøget biologisk aktivitet
DE69017874T2 (de) EPROM-Anordnung mit metallenen Source-Anschlüssen und ihre Herstellung.
IL75133A0 (en) Derivatives of glycerophosphocholine and glycerophosphoethanolamine,their preparation and their use
NO871053L (no) Anvendelse av substituerte n-triklormetyltiodikarboksimider i kombinasjon med n,n[-substituerte bis-(2,4-diamino-s-triazin-6-yl)-oligosulfider i vulkaniserbare kautsjukblandinger og slike kautsjukblandinger.
DE69230798T2 (de) Rekombinante immuntoxine
DE3780598T2 (de) Bauelemente und bauelemente-herstellung mit borsilikatglass.
NZ230155A (en) N-2,3-butadienyl-n"-substituted-triamindalkanes and alkenes, and pharmaceutical compositions
ATE58639T1 (de) Appetit mildernde und gegen gastritis wirksame zusammensetzung.
NO894008D0 (no) Trekonserveringsmiddel og fremgangsmaate for behandling avtre med samme.
FR2355505A1 (fr) Nouvel agent adjuvant immunitaire
DE3881099D1 (de) Acrylkautschuk, zusammensetzung aus acrylkautschuk und gegenstaende aus vernetztem acrylkautschuk.
ES2061566T3 (es) Anticuerpos monoclonales contra la proteina e7 del papilomavirus humano tipo 16, procedimiento para su preparacion, asi como su empleo.
ZA849576B (en) 1,7-diphenyl-3-methyllaza-7-cyano-8-methylnonane for use in the treatment of diseases
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
IL84040A0 (en) Monoclonal antibodies against ifn-omega,their preparation and their use in the purification and detection of ifn-omega
AU561309B2 (en) Diarylindane-1,3-diones
ATE69549T1 (de) Erzeugnisse, enthaltend gallopamil und prazosin.
DE3587351D1 (de) Haemoglobin mit reduziertem virusrisiko und dessen herstellung.
FI885025A (fi) Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning.
DE68913124D1 (de) Terpolymer und transparenter Schichtstoff mit ausgezeichneten optischen Eigenschaften.
GR3005231T3 (xx)
ES8706665A1 (es) Procedimiento de preparar nuevas sales de acidos carboxilicos, terapeuticamente utiles